In a note out this morning, analyst David Risinger of Morgan Stanley lowered his rating on Bristol Myers BMY from Overweight to Equal-Weight, but maintained his $60 price objective.
The change is attributed to the recent rally in the shares, with BMY having rallied 17 percent since October 2. With the stock now trading just below the $60 price target (closed at $58.61), he feels an equal-weight rating is now appropriate.
Morgan Stanley Investment Thesis
-We expect rising pipeline enthusiasm to drive stock outperformance.
-BMY should trade at a significant premium to group P/E due to strong pipeline.
-BMY stock is likely to be volatile (positive/negative) on immuno-oncology (nivo, or PD-1) newsflow.
Shares of BMY are trading slightly lower in pre-market trade at 58.32
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in